Log in

NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Forecast & News

$88.54
-3.98 (-4.30 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$87.56
Now: $88.54
$92.23
50-Day Range
$75.11
MA: $94.21
$107.62
52-Week Range
$71.85
Now: $88.54
$119.65
Volume753,508 shs
Average Volume976,796 shs
Market Capitalization$8.17 billion
P/E Ratio268.30
Dividend YieldN/A
Beta1.42
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company's product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL - Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders; and a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson's disease and VY-FXN01 program for Friedreich's ataxia. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Read More
Neurocrine Biosciences logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$788.10 million
Cash Flow$0.65 per share
Book Value$6.92 per share

Profitability

Net Income$37.01 million

Miscellaneous

Employees585
Market Cap$8.17 billion
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.


Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

How has Neurocrine Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NBIX stock has increased by 3.1% and is now trading at $88.54. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Neurocrine Biosciences?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neurocrine Biosciences.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Neurocrine Biosciences.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings data on Tuesday, February, 4th. The company reported $0.35 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.75 by $0.40. The company earned $244.10 million during the quarter, compared to analysts' expectations of $231.54 million. Neurocrine Biosciences had a net margin of 4.70% and a return on equity of 8.27%. The company's revenue for the quarter was up 85.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.19 earnings per share. View Neurocrine Biosciences' earnings history.

What price target have analysts set for NBIX?

16 brokerages have issued 1-year price targets for Neurocrine Biosciences' shares. Their forecasts range from $88.00 to $153.00. On average, they expect Neurocrine Biosciences' stock price to reach $117.07 in the next year. This suggests a possible upside of 32.2% from the stock's current price. View analysts' price targets for Neurocrine Biosciences.

Has Neurocrine Biosciences been receiving favorable news coverage?

News coverage about NBIX stock has been trending extremely negative this week, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neurocrine Biosciences earned a news sentiment score of -5.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutNeurocrine Biosciences.

Are investors shorting Neurocrine Biosciences?

Neurocrine Biosciences saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 4,930,000 shares, an increase of 13.6% from the February 13th total of 4,340,000 shares. Based on an average daily volume of 825,600 shares, the days-to-cover ratio is presently 6.0 days. Approximately 5.4% of the shares of the stock are short sold. View Neurocrine Biosciences' Current Options Chain.

Who are some of Neurocrine Biosciences' key competitors?

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Micron Technology (MU), Netflix (NFLX), Gilead Sciences (GILD), salesforce.com (CRM), Twilio (TWLO), Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX).

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the following people:
  • Dr. Kevin C. Gorman, CEO & Director (Age 61)
  • Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)
  • Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)
  • Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)
  • Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62)

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (7.99%), Capital International Investors (6.32%), Perceptive Advisors LLC (3.91%), Perceptive Advisors LLC (3.91%), Alliancebernstein L.P. (1.34%) and Geode Capital Management LLC (1.12%). Company insiders that own Neurocrine Biosciences stock include Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin. View institutional ownership trends for Neurocrine Biosciences.

Which major investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Janus Henderson Group PLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Russell Investments Group Ltd., Pictet Asset Management Ltd., Marshall Wace North America L.P., and Nuveen Asset Management LLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, and Matt Abernethy. View insider buying and selling activity for Neurocrine Biosciences.

Which major investors are buying Neurocrine Biosciences stock?

NBIX stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Renaissance Technologies LLC, Sumitomo Mitsui Trust Holdings Inc., Victory Capital Management Inc., Victory Capital Management Inc., Parkman Healthcare Partners LLC, 1832 Asset Management L.P., and Swiss National Bank. View insider buying and selling activity for Neurocrine Biosciences.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $88.54.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $8.17 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe. View additional information about Neurocrine Biosciences.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is http://www.neurocrine.com/.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]


MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  849 (Vote Outperform)
Underperform Votes:  311 (Vote Underperform)
Total Votes:  1,160
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel